NAGLAZYME (Galsulfage) Logo

(* Required field)

First Name*

Last Name*

E-Mail*

Confirm E-Mail*

Address 1

Address 2

City

State*

Zip Code*

Country*

Phone

Year of Birth*

Gender*

MaleFemale

Are you a HCP?*

Yes No

IMPORTANT SAFETY INFORMATION

NAGLAZYME^® is indicated for patients with Mucopolysaccharidosis VI (MPS VI). NAGLAZYME^® has been shown to improve walking and stair-climbing capacity.

The most common adverse events observed in clinical trials in patients treated with NAGLAZYME^® were headache, fever, joint pain, vomiting, upper respiratory infections, abdominal pain, diarrhea, ear pain, cough, and ear infections. Severe reactions included swollen blood vessels, low blood pressure, difficulty breathing, respiratory distress, stopping breathing, and hives. The most common symptoms of infusion reactions included fever, chills/shakes, headache, rash and mild to moderate hives. Nausea, vomiting, elevated blood pressure, chest pain, abdominal pain, malaise, and joint pain were also reported.

Please see full prescribing information (PDF 440KB)

Region:

Text Size

NAGLAZYME (Galsulfage) Logo

Sign Up for E-Mail Updates

IMPORTANT SAFETY INFORMATION